The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick pickspolarean Regulatory News (POLX)

Share Price Information for polarean (POLX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.70
Bid: 3.60
Ask: 3.80
Change: 0.05 (1.37%)
Spread: 0.20 (5.556%)
Open: 3.65
High: 3.70
Low: 3.68
Prev. Close: 3.65
POLX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Nominated Adviser Status

5 Nov 2018 07:00

RNS Number : 2568G
Polarean Imaging PLC
05 November 2018
 

 

5 November 2018

Polarean Imaging Plc 

("Polarean" or the "Company")

 

Nominated Adviser Status

Polarean Imaging plc (AIM: POLX), the medicalimaging technology company, with a proprietary drugdevice combination product for the magnetic resonance imaging (MRI) market, announces that the Company's directors are aware of the proposed merger of its current nominated adviser ("Nomad"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP ("SP Angel"). 

It is the intention of the directors to replace the Company's Nomad role with SP Angel.

The directors have also been informed that Northland has voluntarily agreed to relinquish its Nomad status and will be removed from the register of Nomads with effect from 7am on 1 February 2019.

Furthermore, the Company recognises that Northland's merger with SP Angel remains subject to regulatory approvals and due diligence. In accordance with AIM Rule 1, if the Company fails to appoint a new Nomad by 1 February 2019 the Exchange will suspend trading in the Company's AIM Securities. If the Company has failed to appoint a replacement Nomad by 4 March 2019 the admission of its AIM Securities will be cancelled.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

 

Polarean Imaging plc

www.polarean.com / www.polarean-ir.com

Richard Hullihen, Chief Executive Officer

Via Walbrook PR

Richard Morgan, Chairman

 

Northland Capital Partners Limited

Tel: +44 (0)20 3861 6625

David Hignell / Gerry Beaney / Jamie Spotswood (Corporate Finance)

Rob Rees (Corporate Broking)

MC Services (European IR)

Tel: +49 (0)89 210 2280

Raimund Gabriel

The Life Sciences Division (Financial Adviser)

Navid Malik, Director

Mob: 07957 224 730

Alia Minhas, CEO

Mob: 07590 696 057

Walbrook PR

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com

Paul McManus / Anna Dunphy

Helen Cresswell

Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001

+44 (0)7841 917 679

 

 

About Polarean (www.polarean.com)

 

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
APPBRBDBBDGBGID
Date   Source Headline
23rd Oct 20202:05 pmRNSSecond Price Monitoring Extn
23rd Oct 20202:00 pmRNSPrice Monitoring Extension
20th Oct 20207:00 amRNSExercise of warrants
14th Oct 202011:00 amRNSPrice Monitoring Extension
12th Oct 20204:40 pmRNSSecond Price Monitoring Extn
12th Oct 20204:35 pmRNSPrice Monitoring Extension
12th Oct 20207:00 amRNSNew System Order
8th Oct 20205:05 pmRNSHolding(s) in Company
7th Oct 20207:00 amRNSNDA Submission
30th Sep 20207:00 amRNSHalf-year Report
18th Sep 20207:00 amRNSNew System Installation
30th Jul 20207:00 amRNSScientific presentations on hyperpolarized Xenon
13th Jul 20202:23 pmRNSResult of AGM
18th Jun 20207:00 amRNSFinal Results
1st Jun 20207:00 amRNSAppointment of Non-Executive Director
1st Jun 20207:00 amRNSExercise of Warrants
11th May 202011:05 amRNSSecond Price Monitoring Extn
11th May 202011:00 amRNSPrice Monitoring Extension
30th Apr 20206:30 pmRNSTotal Voting Rights
2nd Apr 20205:06 pmRNSHolding(s) in Company
2nd Apr 20202:12 pmRNSHolding(s) in Company
1st Apr 20203:32 pmRNSResult of General Meeting & Fundraise Completion
31st Mar 20207:00 amRNSTotal Voting Rights
25th Mar 20207:00 amRNSGeneral Meeting: Change of Venue
13th Mar 202012:51 pmRNSConditional Fundraise to raise £8.4 million
12th Mar 20204:41 pmRNSSecond Price Monitoring Extn
12th Mar 20204:36 pmRNSPrice Monitoring Extension
2nd Mar 20207:00 amRNSExercise of Warrants
3rd Feb 20207:00 amRNSDirectorate Change
29th Jan 20207:00 amRNSPositive pivotal Phase III Clinical Trials results
22nd Jan 20204:03 pmRNSDirector Dealing
13th Jan 20207:00 amRNSHolding(s) in Company
2nd Jan 20204:50 pmRNSDirector dealing
24th Dec 20197:00 amRNSNew System Delivery and Installation
12th Nov 20197:00 amRNSNew System Delivery and Installation
8th Nov 20197:00 amRNSGrant of options
7th Nov 20197:00 amRNSCompletion of patient enrolment & PDMR appointment
11th Oct 20194:17 pmRNSDirector dealing
11th Oct 20197:01 amRNSPolarean notes statement from Amphion Innovations
9th Oct 20197:00 amRNSHolding(s) in Company
3rd Oct 20197:00 amRNSPolarean notes statement from Amphion Innovations
25th Sep 20197:00 amRNSPolarean notes statement from Amphion Innovations
24th Sep 20197:00 amRNSHalf-year Report
10th Sep 20195:15 pmRNSPolarean notes statement from Amphion Innovations
10th Sep 20197:00 amRNSNew System Installation
9th Aug 20194:14 pmRNSStatement on Amphion Innovations
5th Aug 20197:00 amRNSPhase III Clinical Trials update
31st Jul 201910:04 amRNSTotal Voting Rights
30th Jul 20193:18 pmRNSHolding(s) in Company
30th Jul 20192:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.